Asunto(s)
Transfusión Feto-Fetal/patología , Trombocitemia Esencial/patología , Gemelos Monocigóticos , Adolescente , Enfermedades en Gemelos/genética , Enfermedades en Gemelos/patología , Femenino , Transfusión Feto-Fetal/genética , Humanos , Intercambio Materno-Fetal/genética , Embarazo , Trombocitemia Esencial/genéticaRESUMEN
AIM: To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital. METHODS: Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital. RESULTS: 189 patients (age 76.0 ± 9.4 years; CHA2DS2-VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively. CONCLUSION: In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.